Author + information
- S1936879815020257-543ec06e163a5b3a639fccaa1083ff14Jong-Bum Kwon,
- S1936879815020257-87e3650ca775d2cb8c06ed648a7d9bd0Gyung-Min Park,
- S1936879815020257-b6161377b28a4c897e97ddacfc457e2fDae Won Kim,
- S1936879815020257-de253259bb214ba0969f574143259e46Tae-Seok Kim,
- S1936879815020257-4076e75733183691d76d8efbcccdaff6Chan Joon Kim,
- S1936879815020257-e4d3c7f728a104f052dc29b87ddf2e04Jung Sun Cho,
- S1936879815020257-8a08cac4cd9d4addfaf8f26fa0e0960aMahn-Won Park and
- S1936879815020257-cb58f5bc693315cc1f8356905b88ca88Sung Ho Her
There are limited data to compare the clinical benefits between moderate- and high-intensity statin therapy in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI).
From national health insurance claims data in South Korea, patients aged 18 years or older without known history of coronary artery disease, who underwent PCI as a diagnosis of AMI between 2009 and 2013, were enrolled. According to the intensity of statin therapy, patients were categorized into moderate-intensity (n=17,572) and high-intensity statin therapy (n=4,002) groups. Clinical outcomes were compared between two groups.
The average age of study participants was 62.1 years and 16,148 (74.8 %) were men. Diabetes mellitus, hyperlipidemia, and hypertension were observed in 6,362 (29.5%), 4,452 (20.6%), and 8,724 (40.4%) patients, respectively. During the follow-up period (median, 2.4 years; interquartile range, 1.5-3.5), there was no significant difference in the incidence of all-cause death between both groups (adjusted hazard ratio [aHR] of high-intensity statin therapy, 0.887; 95% confidence interval [CI]: 0.713-1.105; p=0.284). In addition, the incidence rates of recurrent revascularization (aHR, 0.969; 95% CI: 0.868-1.082; p=0.574), coronary artery disease related hospitalization (aHR, 1.011; 95% CI: 0.963-1.062; p=0.651), and congestive heart failure related hospitalization (aHR, 1.020; 95% CI: 0.907-1.147; p=0.738) did not differ between two groups.
In South Korean patients with AMI undergoing PCI, high-intensity statin therapy did not provide incremental clinical benefits over moderate-intensity therapy.